MARKET

MNOV

MNOV

Medicinova
NASDAQ
1.395
-0.005
-0.36%
After Hours: 1.395 0 0.00% 16:15 11/13 EST
OPEN
1.400
PREV CLOSE
1.400
HIGH
1.445
LOW
1.390
VOLUME
61.65K
TURNOVER
--
52 WEEK HIGH
3.900
52 WEEK LOW
1.220
MARKET CAP
68.66M
P/E (TTM)
-6.3757
1D
5D
1M
3M
1Y
5Y
1D
MediciNova (MNOV) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 2d ago
Weekly Report: what happened at MNOV last week (1102-1106)?
Weekly Report · 5d ago
Weekly Report: what happened at MNOV last week (1026-1030)?
Weekly Report · 11/02 09:44
Weekly Report: what happened at MNOV last week (1019-1023)?
Weekly Report · 10/26 09:44
Weekly Report: what happened at MNOV last week (1012-1016)?
Weekly Report · 10/19 09:44
MediciNova CEO provides update on results from Phase 2 trial of MN-001
TipRanks · 10/12 10:16
MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance
Benzinga · 10/12 10:07
Weekly Report: what happened at MNOV last week (1005-1009)?
Weekly Report · 10/12 09:47
More
About MNOV
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.

Webull offers Medicinova Inc stock information, including NASDAQ: MNOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNOV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNOV stock methods without spending real money on the virtual paper trading platform.